Furthermore, single-AAV-delivered base editing systems have been developed to efficiently and precisely edit pathogenic single-nucleotide polymorphisms [48], and our mini-Myo15 promoter can also be used in gene therapy of dominant nonsyndromic hearing loss using such systems. The gene discussed is MYO15A; the disease is hearing loss disorder.